仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Tildrakizumab （SCH 900222） is a humanized anti-IL-23 （p19 subunit） monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 （Kd: 136 pM）. Tildrakizumab is effective against moderate to severe plaque psoriasis